{"id":972,"date":"2026-03-19T01:56:18","date_gmt":"2026-03-19T08:56:18","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=972"},"modified":"2026-03-24T13:54:58","modified_gmt":"2026-03-24T20:54:58","slug":"lcotyde-a-new-psoriasis-treatment-pill","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/lcotyde-a-new-psoriasis-treatment-pill\/","title":{"rendered":"Icotyde – a new psoriasis treatment pill"},"content":{"rendered":"\n

The U.S. Food and Drug Administration has approved Icotyde (icotrokinra)<\/strong> for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents 12 years and older who weigh at least 40 kg. This is notable because Icotyde is an oral, once-daily medication that targets the IL\u201123 receptor<\/strong>, a key part of the immune pathway that drives many cases of plaque psoriasis.<\/p>\n\n\n\n

If you or someone you care for has been struggling with persistent plaques, frequent flares, or the hassle of injections, this approval could change how treatment is approached. Below is a clear, practical breakdown of what Icotyde is, how it performed in trials, how it compares to other options, and what to watch for next.<\/p>\n\n\n\n

What is Icotyde and how does it work?<\/strong><\/h3>\n\n\n\n

Icotyde is a small peptide drug taken as a pill once a day. It works by blocking the interleukin\u201123 receptor (IL\u201123R)<\/strong> on immune cells. IL\u201123 is a signaling protein that helps drive inflammation in psoriasis; by stopping the receptor, Icotyde reduces the inflammatory signals that cause skin cells to grow too quickly and form plaques.<\/p>\n\n\n\n

The important point for most people: Icotyde aims to give the benefits of modern biologic therapies (strong, targeted control of psoriasis) in an oral form rather than an injection or infusion.<\/p>\n\n\n\n

How well did Icotyde work in clinical trials?<\/strong><\/h3>\n\n\n\n

The FDA approval was based on a large clinical program that included about 2,500 patients across multiple Phase 3 studies. In head\u2011to\u2011head trials against an active comparator, roughly 70% of patients reached \u201cclear or almost clear\u201d skin by investigator assessment (IGA 0\/1) and about 55% achieved a PASI 90 response (meaning a 90% improvement in the Psoriasis Area and Severity Index) by Week 16. These are strong results for a pill.<\/p>\n\n\n\n

Safety data showed that rates of adverse reactions in Icotyde\u2011treated patients were very close to placebo through Week 16, and no new safety signals were identified through one year of follow\u2011up in the trials. That said, every medicine has potential side effects, and long\u2011term real\u2011world experience will add more clarity.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
\n
See Your Ranked Personalized Treatments<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n

Quick comparison: Icotyde versus common psoriasis treatments<\/strong><\/h3>\n\n\n\n
Feature<\/strong><\/td>Icotyde (oral pill)<\/strong><\/td>Injectable biologics (IL\u201123\/IL\u201117 inhibitors)<\/strong><\/td>Topical creams\/ointments<\/strong><\/td><\/tr>
How given<\/strong><\/td>Once\u2011daily oral tablet<\/td>Injection (varies: weekly to every few months)<\/td>Applied to skin<\/td><\/tr>
Target<\/strong><\/td>IL\u201123 receptor<\/td>IL\u201123 or IL\u201117 pathway proteins<\/td>Local skin inflammation<\/td><\/tr>
Typical speed of effect<\/strong><\/td>Rapid (weeks)<\/td>Rapid to moderate (weeks)<\/td>Slower; limited for widespread disease<\/td><\/tr>
Efficacy in trials<\/strong><\/td>~55% PASI 90 at Week 16 in head\u2011to\u2011head studies<\/td>Many biologics show high PASI 90 rates; varies by drug<\/td>Useful for mild disease only<\/td><\/tr>
Convenience<\/strong><\/td>High (pill)<\/td>Lower (injections\/clinic visits)<\/td>High for mild\/localized disease<\/td><\/tr>
Safety monitoring<\/strong><\/td>Routine checks recommended<\/td>Routine checks recommended<\/td>Minimal systemic monitoring<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This table simplifies complex data, but it highlights the main tradeoffs: convenience (oral pill) versus the well\u2011established track record of injectable biologics. The approval positions Icotyde as an option for people who need systemic therapy but prefer a pill.<\/p>\n\n\n\n

Who might be a candidate for Icotyde?<\/strong><\/h3>\n\n\n\n

The FDA label specifies adults and adolescents 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. In plain terms, that means people whose psoriasis is moderate to severe, or whose disease affects quality of life enough that topical creams aren\u2019t enough. Your dermatologist will consider factors such as how much skin is affected, whether joints are involved, prior treatments, other health conditions, and personal preferences.<\/p>\n\n\n\n

Safety and monitoring  –  what to expect<\/strong><\/h3>\n\n\n\n

Clinical trials reported that adverse reaction rates for Icotyde were similar to placebo through the early weeks of treatment, and no new safety signals were seen through one year. Still, standard practice with systemic psoriasis drugs includes baseline health checks and periodic monitoring (for example, screening for infections, liver tests, or other labs as recommended by your doctor). If you have a history of infections, immune problems, or other chronic conditions, discuss these with your clinician before starting any systemic therapy.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
\n
Quickly Understand Treatment Risks<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n

Practical things patients often ask<\/strong><\/h3>\n\n\n\n